Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Lorefice L, Schoonheim MM, Morrow SA, Ann Picone M, Pardo G, Zarif M, Gudesblatt M, Nicholas JA, Smith A, Hunter S, Newman S, AbdelRazek MA, Hoti I, Riolo J, Silva D, Fuchs TA, Dwyer MG, Hb Benedict R. Zivadinov R, et al. Among authors: nicholas ja. Neuroimage Clin. 2024 Apr 27;42:103609. doi: 10.1016/j.nicl.2024.103609. Online ahead of print. Neuroimage Clin. 2024. PMID: 38718640 Free PMC article.
Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
Sotirchos ES, Hu C, Smith MD, Lord HN, DuVal AL, Arrambide G, Montalban X, Akgün K, Ziemssen T, Naismith RT, Hersh CM, Hyland M, Krupp LB, Nicholas JA, Bermel RA, Mowry EM, Calabresi PA, Fitzgerald KC. Sotirchos ES, et al. Among authors: nicholas ja. Neurology. 2023 Dec 4;101(23):e2448-e2453. doi: 10.1212/WNL.0000000000207957. Neurology. 2023. PMID: 37816633
Associations of sNfL with clinico-radiological measures in a large MS population.
Sotirchos ES, Fitzgerald KC, Singh CM, Smith MD, Reyes-Mantilla M, Hersh CM, Hyland MH, Canissario R, Simmons SB, Arrambide G, Montalban X, Comabella M, Naismith RT, Qiao M, Krupp LB, Nicholas JA, Akgün K, Ziemssen T, Rudick R, Fisher E, Bermel RA, Mowry EM, Calabresi PA. Sotirchos ES, et al. Among authors: nicholas ja. Ann Clin Transl Neurol. 2023 Jan;10(1):84-97. doi: 10.1002/acn3.51704. Epub 2022 Nov 25. Ann Clin Transl Neurol. 2023. PMID: 36427295 Free PMC article.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Wray S, Jacques F, Miller TA, Nicholas JA, Arroyo R, Travis L, Khatri B, Chirieac M, Gandhi R, Roesch N, Rodrigues A, Melas-Melt L, Rawlings AM, Hunter SF. Wray S, et al. Among authors: nicholas ja. Mult Scler J Exp Transl Clin. 2022 Nov 15;8(4):20552173221135888. doi: 10.1177/20552173221135888. eCollection 2022 Oct-Dec. Mult Scler J Exp Transl Clin. 2022. PMID: 36407472 Free PMC article.
Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy.
Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Manca L, Harlow DE, Phillips AL. Nicholas JA, et al. Mult Scler J Exp Transl Clin. 2022 Jun 30;8(2):20552173221101150. doi: 10.1177/20552173221101150. eCollection 2022 Apr-Jun. Mult Scler J Exp Transl Clin. 2022. PMID: 35795102 Free PMC article.
157 results